Characterization of Nitric Oxide Release by Nebivolol and Its Metabolites

American Journal of Hypertension

Volumn 19, Issue 6, 2006, Pages 579-586

  Maffei, Angelo ^a   Vecchione, Carmine ^a   Aretini, Alessandra ^a   Poulet, Roberta ^a   Bettarini, Umberto ^a   Gentile, Maria Teresa ^a   Cifelli, Giuseppe ^a   Lembo, Giuseppe ^a,b  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

adrenoceptor antagonists; endothelium; Nitric oxide

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEBIVOLOL; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERY RESISTANCE; ARTICLE; CONDUCTANCE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; HISTOLOGY; HUMAN; HUMAN CELL; LIVER METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AORTA; BENZOPYRANS; CALCIUM; CAROTID ARTERIES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; HUMANS; ISOMERISM; MALE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; RATS; RATS, INBRED WKY; RECEPTORS, ADRENERGIC, BETA-1; VASODILATOR AGENTS;

EID: 33646823953     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2005.09.021     Document Type: Article

References (22)

1. Mangrella M., Rossi F., Fici F., and Rossi F. Pharmacology of nebivolol. Pharmacol Res 38 (1998) 419-431
2. Gao Y.S., Nagao T., Bond R.A., Janssens W.J., and Vanhoutte P.M. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 17 (1991) 964-969
3. Dawes M., Brett S.E., Chowienczyk P.J., Mant T.G., and Ritter J.M. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 48 (1999) 460-463
4. Tzemos N., Lim P.O., and MacDonald T.M. Nebivolol reverses endothelial dysfunction in essential hypertension. a randomized, double-blind, crossover study. Circulation 104 (2001) 511-514
5. Cockcroft J.R., Chowienczyk P.J., Brett S.E., Chen C.P., Dupont A.G., Van Nueten L., Wooding S.J., and Ritter J.M. Nebivolol vasodilates human forearm vasculature. evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 274 (1995) 1067-1071
6. Kalinowski L., Dobrucki L.W., Szczepanska-Konkel M., Jankowski M., Martyniec L., Angielski S., and Malinski T. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux. a novel mechanism for antihypertensive action. Circulation 107 (2003) 2747-2752
7. Parenti A., Filippi S., Amerini S., Granger H.J., Fazzini A., and Ledda F. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther 292 (2000) 698-703
8. Gosgnach W., Boixel C., Nevo N., Poiraud T., and Michel J.B. Nebivolol induces calcium-independent signaling in endothelial cells by a possible beta-adrenergic pathway. J Cardiovasc Pharmacol 38 (2001) 191-199
9. Broeders M.A., Doevendans P.A., Bekkers B.C., Bronsaer R., van Gorsel E., Heemskerk J.W., Egbrink M.G., van Breda E., Reneman R.S., and van Der Zee M. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 102 (2000) 677-684
10. Chlopicki S., Kozlovski V.I., and Gryglewski R.J. NO-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors. J Physiol Pharmacol 53 (2002) 615-624
11. Cominacini L., Fratta Pasini A., Garbin U., Nava C., Davoli A., Criscuoli M., Crea A., Sawamura T., and Lo Cascio V. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol 42 (2003) 1838-1844
12. Maffei A., Poulet R., Vecchione C., Colella S., Fratta L., Frati G., Trimarco V., Trimarco B., and Lembo G. Increased basal nitric oxide release despite enhanced free radical production in hypertension. J Hypertens 20 (2002) 1135-1142
13. Vecchione C., Patrucco E., Marino G., Barberis L., Poulet R., Aretini A., Maffei A., Gentile M.T., Storto M., Azzolino O., Brancaccio M., Colussi G.L., Bettarini U., Altruda F., Silengo L., Tarone G., Wymann M.P., Hirsch E., and Lembo G. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kγ. J Exp Med 201 (2005) 1217-1228
14. Kamali F., Howes A., Thomas S.H., Ford G.A., and Snoeck E. A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. Br J Clin Pharmacol 43 (1997) 201-204
15. Cohn J.N. Vascular wall function as a risk marker for cardiovascular disease. J Hypertens 17 (1999) S41-S44
16. Muller B., Kleschyov A.L., Gyorgy K., and Stoclet J.C. Inducible NO synthase activity in blood vessels and heart. new insights into cell origin and consequences. Physiol Rev 49 (2000) 19-26
17. Ignarro L.J., Byrns R.E., Trinh K., Sisodia M., and Buga G.M. Nebivolol. a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide 7 (2002) 75-82
18. Janssens W.J. Pharmacology of nebivolol. J Pharm Belg 47 (1992) 323-327
19. Stoleru L., Wijns W., van Eyll C., Bouvy T., Van Nueten L., and Pouleur H. Effects of D-nebivolol and l-nebivolol on left ventricular systolic and diastolic function. comparison with D-l-nebivolol and atenolol. J Cardiovasc Pharmacol 22 (1993) 183-190
20. Xhonneux R., Wouters L., Reneman R.S., and Janssen P.A. The l-enantiomer of nebivolol potentiates the blood pressure lowering effect of the d-enantiomer. Eur J Pharmacol 181 (1990) 261-265
21. Cheymol G., Woestenborghs R., Snoeck E., Ianucci R., Le Moing J.P., Naditch L., Levron J.C., and Poirier J.M. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 51 (1997) 493-498
22. Kobayashi N., Mita S., Yoshida K., Honda T., Kobayashi T., Hara K., Narano S., Tsubokou Y., and Matsuoka H. Celiprolol activates eNOS through the PI3K/Akt pathway and inhibits VCAM-1 via NF-kB induced by oxidative stress. Hypertension 42 (2003) 1004-1013